GleamWall
中文EN

BBIO BridgeBio Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1743881 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY167.3%
TTM net income YoY29.0%
TTM EPS YoY28.0%
Revenue 3-yr CAGR364.6%
Net income 3-yr CAGR—

Margins

Gross margin94.3%
Operating margin-38.5%
Net margin-59.8%
FCF margin-39.1%
EBITDA margin-38.0%

Returns

ROE—
ROA-35.8%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets176.5%
Debt / equity—
Current ratio2.09x
Interest coverage-7.13x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$502.08M$221.90M
Cost of revenue$20.96M$3.88M
Gross profit$481.11M$218.02M
R&D expense$451.95M$506.46M
SG&A expense$531.23M$288.93M
Operating income-$523.41M-$592.97M
Interest expense$53.10M$90.99M
Pretax income-$732.50M-$542.19M
Income tax$435,000$1.15M
Net income-$724.93M-$535.76M
EBITDA-$517.98M-$586.90M
EPS (basic)-3.78-2.88
EPS (diluted)-3.78-2.88
Weighted avg. shares (diluted)191.53M186.08M
Balance sheet
Cash & equivalents$570.12M$681.10M
Short-term investments$17.36M$0
Receivables$139.44M$4.72M
Inventory$26.75M$0
Current assets$797.75M$720.69M
PP&E, net$5.37M$7.01M
Intangibles$28.08M$23.93M
Total assets$936.02M$919.34M
Current liabilities$287.97M$154.40M
Long-term debt$2.01B$437.34M
Total debt$2.01B$437.34M
Total liabilities$3.01B$2.38B
Shareholders' equity-$2.09B-$1.47B
Net debt$1.44B-$243.76M
Shares outstanding194.77M190.04M
Cash flow statement
Operating cash flow-$445.91M-$520.73M
Capital expenditure$1.10M$933,000
Free cash flow-$447.01M-$521.66M
Investing cash flow-$24.49M$60.78M
Financing cash flow$359.29M$748.46M
Depreciation & amortization$5.43M$6.08M
Stock-based compensation$133.02M$95.80M
Share buybacks$48.28M$0

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.